Achilles Therapeutics Plc (ACHL)

[jondoeuk]

In a case study from the ongoing THETIS trial, a patient diagnosed with melanoma received a three cycle combination of Yervoy and Opdivo which was stopped due to toxicity. Last year, they had a recurrent lesion excised and cNeT manufactured through the VELOS process. The specificity and fitness of the cNeT were measured by flow cytometric analysis of IFN-y and TNF-a cytokines, markers of T-cell activity. Up to 53% of the T-cells in the manufactured product were reactive to the patient's own clonal neoantigens following stimulation. The cNeT can be tracked after dosing by using peptides that incorporate patient-specific clonal mutations from the tumour to stimulate cells from the blood of the patient. By using ELISpot technology to detect cNeT that produce cytokine in response to this stimulus, the expansion and persistence of cNeT in circulation can be calculated.

https://ir.achillestx.com/static-files/eefe8e60-023f-4beb-9681-44e4451032bc